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The rapid action of the long acting beta agonist formoterol allows it to be used as both
a preventer and reliever in the management of asthma. The Symbicort SMART dosing regime
has been shown to reduce the number of asthma exacerbations.
The aim was to determine the current prescribing of Symbicort, the prescribing of the
SMART regimen and the co-prescribing of a short acting beta agonist with this regimen by
means of an audit of prescriptions dispensed in a pharmacy multiple in the UK.
Anonymised data were collected on a standard form. Symbicort prescribing data for six
months were extracted from the pharmacy Patient Medication Record (PMR). Data were strat-
ified by age and analysed to determine adherence with Symbicort SMART prescribing as
defined by the UK product license.
Data were received from 51 of the 118 (43.2%) pharmacies contacted. Complete information
from 2484 PMRs was included in the study. 2.81% (70/2484) of patients were prescribed SMART
as defined by the UK summary of product characteristics. Of the 18e35 year age group 7.44%
(27/363) were prescribed SMART correctly. However, Symbicort was prescribed twice a day
and when required, with either the co-prescription of a SABA, or at an unlicensed dose in
2.46% (61/2484) and 0.28% (7/2484) patients respectively.
The incidence of Symbicort SMART prescribing in this study is low but may be underesti-
mated due to unclear dosing instructions.
ª 2010 Elsevier Ltd. All rights reserved.)141 548 4594; fax: þ44 (0)141 552 2562.
h.ac.uk (A.C. Boyter).
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2516 patient’s data 
received
2484 patients* 
2304 patients included in 
study
Patients under 18 
114
Patients 18-35 
363
Patients over 35 
1826
180 patients excluded 
because no age was 
recorded
32 patients excluded 
because no dosage 
information was recorded
Figure 1 Number of patients in each age group. )All 2484
patients were included in the analyses that did not specify age
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Long acting beta agonists (LABA) have changed the way in
which patients with chronic asthma are managed. The
benefits of adding a LABA to existing inhaled corticosteroid
therapy are well documented and include, improved
symptom control and a reduction in the number of mild and
severe exacerbations.1,2 However, in a recent study3, LABA
were shown to be associated with worsening of asthma
control when prescribed without an inhaled corticosteroid
(ICS). TheMedicines andHealth Regulatory Authority (MHRA)
now advise that LABAs should only be prescribed to patients
with asthma already prescribed an inhaled corticosteroid.4
This co-prescribing may be facilitated by the use of
a combination device containing both a LABA and an ICS.
Although these devices do not offer additional symptomatic
control, theymay improve adherence to dosing regimes5 and
ensure that both the LABA and ICS are inhaled.
In the UK there are two licensed LABAs; formoterol and
salmeterol. Both agents have a duration of action of about
12 h but formoterol has an onset of action which is more
rapid than salmeterol and similar to that of salbutamol.6,7
Due to this rapid onset of action formoterol has been
shown to be an effective reliever medication8, and has a UK
license as reliever medication in asthma. Palmqvist et al.9
(2001) suggested that the combination of an ICS and LABA
would also be suitable as relief medication and could allow
patients to adjust their dosing regime according to their
symptoms.
A recent Cochrane review has shown that the combina-
tion preparation of budesonide and formoterol
(Symbicort) is effective as both maintenance and reliever
therapy.10 This dosage regime which allows the patient to
use their Symbicort Turbohaler (100/6 or 200/6 equivalent
to 80/4.5 and 160/4.5 as the delivered dose respectively)
twice a day and when required for symptomatic relief has
been termed SMART (Symbicort Maintenance and Reliever
Therapy). Studies have shown that this dosing regime can
reduce the number of severe exacerbations and lower the
overall steroid burden, in poorly controlled asthma, in
comparison to traditional regimes.11e13 In addition, if
a combination inhaler is used for both maintenance and
reliever therapy then the patient should only require one
inhaler as a short acting beta agonist (SABA) will no longer
be required. This statement assumes that the SMART
regimen has been prescribed correctly; that SABA treat-
ment has been stopped, and the patient understands and
follows the treatment appropriately. The problems associ-
ated with incorrectly co-prescribing a SABA with the SMART
regime are cost, potentially excessive use of beta agonists
and confusion about inhaler dosing schedules.
Recently the update to SIGN/BTS guideline for the
management of asthma (July 2009) included this regime as
an alternative add-on therapy for patients not controlled at
step 3 and for patients uncontrolled at step 24:
This study aims to describe the current prescribing of
Symbicort from the perspective of prescriptions dispensed
within a large pharmacy multiple, to describe the
prescribing of this agent as a maintenance and reliever
therapy and to describe the co-prescribing of a SABA with
the SMART regimen.Methods
Datawere collected on a standard data collection formduring
July 2009. All 118 branches of a large UK pharmacy multiple,
where a pre-registration pharmacist trainee was located,
were prompted to respond to the request for data. Data were
extracted from the pharmacy patient medication record
(PMR) by identifying patients of any age and sex who had
collected a prescription for any strength of Symbicort in the
preceding six months. For data protection purposes, no data
were collected that could identify patients and all PMR print-
outs were shredded after use. As no patient identifiable data
were collected during this audit ethical committee approval
was not required. The data collected included age of the
patient, strength of Symbicort prescribed, dosing instruction
on the prescription, number of inhalers dispensed in the six
month period and whether a SABA was co-prescribed.
Data were entered into a Microsoft Excel spreadsheet by
a single researcher and were validated by checking
a random 10% of the entries.
Returns with incomplete data were excluded from the
study. The Symbicort population was defined by age, inhaler
strength and dosage instructions and prescribing of a SABA.
The data were stratified into four groups:
1. The total population.
2. Under 18 years old; to quantify off-license prescribing
of SMART.
3. Between18and35 years old asCOPD is unlikely in this age
group. In this group a diagnosis of asthma was assumed
but not verified with the General Practitioners records.
4. Over 35 years old; a potentially mixed population of
patients with either asthma or COPD.14Correct prescribing
For the purpose of this audit SMART dosing was defined as;
a prescribed dose of twice a day and as required, patients
over 18 years old, and only either Symbicort 100/6 or 200/6
prescribed. This definition matches the UK summary of
product characteristics for Symbicort15. Dosing instructions
of as directed were deemed to be correct prescribing only if
the doctor specifically provided additional information to
the patient that reflected twice daily and as required dosing.as a parameter.
Table 1 Patients of all ages receiving different inhaler strengths.
Number of patients
All ages
(n Z 2484)
<18
(n Z 114)
18e35
(n Z 363)
>35
(n Z 1826)
Age not specified (n Z 181)
Median age (years)
(IQR)
N/A 13
(11e16)
28
(23e32)
63
(50e72)
N/A
100/6 307 66 57 157 27
200/6 1626 46 268 1186 126
400/12 586 5 41 508 32
N.B: Some patients received more than one strength of inhaler within the 6 month study period.
866 A.C. Boyter et al.Any other dosing instruction, the prescribing of Symbicort
400/12 (equivalent to360/9delivereddose) twicedaily andas
required and the additional prescribing of a SABA were
deemed incorrect.
The Chi-squared test was used to assess the difference
between results from the different age groups.
Results
Data were obtained from 51 of the 118 (43.2%) pharmacies
prompted to respond. No follow-up of non respondents was
undertaken.
Information about 2516 patients was received, of these
2484 had the information required for inclusion in the study
although 181 patients did not have their age specified.
These patients were excluded from the data analysis where
age was used. Data entry validation found an error rate of
0.2%. For patients with an age recorded the median age was
57 years (IQR 39e70) (Fig. 1 and Table 1).
Of the total population 140/2848 (5.64%) patients were
prescribed Symbicort as twice a day and when required and
70/2484 (2.81%) were prescribed SMART dosing as defined
by the UK summary of product characteristics15 (Table 2). In
the 18e35 year age group 27/363 (7.44%) were prescribed
SMART correctly, however, Symbicort was prescribed
twice a day and when required, with either the co-
prescription of a SABA, or at an unlicensed dose in 61/2484
(2.46%) and 7/2484 (0.28%) patients respectively.
The majority of the patient population did not collect
sufficient Symbicort inhalers, of any strength to cover a 6
month period (Table 3). The majority patients of any age
(1745/2484 (70.2%)) had received a SABA in the 6month study
period and of these 61 patients had received Symbicort
prescribed twice daily and when required and a SABA.Table 2 Number of patients receiving each treatment regimen
Symbicort Dosing Instructions Number of patient
Total population 2484
Twice daily (bd) 1976
As directed (mdu) 342
Twice daily and when required (bd þ prn) 140
SMART 70
As required (prn) 49
Other 96
N.B: The numbers exceed the total number of patients included in t
instruction over the 6 month period.Chi-square statistical tests were performed and it was
found that the number of patients using twice a day and as
directed dosing differs significantly between under 18 s and
18e35 s (c2Z 4.47,0.05 < p < 0.02) and between the over
35 s and the 18e35 s (c2 Z 22.96, p < 0.001).
Discussion
Summary of main findings
A wide age range of patients was included in the study
which reflects the mixed nature of respiratory disease
where younger patients present with asthma and older
patients with either asthma or COPD or mixed disease. As
the data were collected from community pharmacies where
the pharmacists do not have access to information about
the diagnosis the decision was made to concentrate on the
18e35 year old population where asthma is the most likely
diagnosis and COPD is less likely.14 The interpretation of
these data could have been made clearer if the GP records
had been interrogated in association with the dispensed
data.
There is a suggestion that a patient is more likely to
receive SMART dosing if they are between the ages of 18
and 35 years in comparison to those under 18 years, in
whom prescribing would be unlicensed or over 35 years,
a population with an increased number of patients with
COPD.14
The number of inhalers dispensed to each patient in this
study was lower than would have been expected, if patient
compliance was good. Assuming that Symbicort had been
prescribed as 1e2 inhalations twice a day, each patient
should have been dispensed between 3 and 6 of the 100/6
and 200/6 inhalers, and 6e12 of the 400/12 inhalers, in the.
s Age <18 Age 18e35 Age >35 No age specified
114 363 1826 181
90 248 1494 144
15 67 235 25
6 40 84 10
e 27 43 e
1 8 36 4
4 4 37 1
he study (2484) as some patients received more than one dosage
Table 3 Number of Symbicort inhalers collected over a six month period.
Over 18 years old
SMART
18e35 years old
SMART
18e35 years old
Non-SMART
Symbicort100/6 n Z 11 n Z 3 n Z 54
Median (IQR) 1 (1e2.5) 1 (1e2.5) 2 (1e2.75)
Symbicort 200/6 n Z 59 n Z 24 n Z 239
Median (IQR) 2 (2e4) 2 (2e3.25) 2 (1e3)
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over the 6 month period was lower than this for both SMART
and non-SMART populations. Our data suggests that
patients do not collect sufficient inhalers for full compli-
ance. This is at odds with the suggestion that SMART dosing
may lead to an overuse of inhalers.16 Under collection of
inhalers in our study may be due to patients using more
than one pharmacy. This may also be an indication of poor
compliance as there is evidence that suggests that only
6e47% of prescriptions written for asthma medication are
dispensed.17 The data in this study could have been
compared to medical databases but as the data were
collected over the whole of the UK this would involve the
interrogation of multiple databases and was outwith the
scope of the study.
Strengths and limitations of the study
The strength of this study is that the data were obtained
from prescriptions dispensed in a large multiple covering all
areas of Great Britain and therefore does not concentrate
on one area of prescribing which may be biased by indi-
vidual prescribers preferences. The main limitation of this
study is the relatively low response rate which may have
been improved by offering incentives for completion of the
paperwork.
Implications for future research or clinical practice
Future studies would benefit from collaborating with other
pharmacies and by obtaining the prescribed as well
dispensed data. This would give a clearer picture of patient
compliance and whether patients prescribed Symbicort
SMART receive a different quantity of inhalers from
patients prescribed the more traditional regimens. Details
of diagnosis would also clarify the population to be
included.
Conclusion
In this study 2.81% of patients were prescribed Symbicort
SMART although we are aware that this may be an under-
estimation of the actual population. In addition, the total
number of Symbicort inhalers ordered over the 6 month
period was less than would be expected if all patients were
compliant and used the same pharmacy for every repeat
prescription. The true reason for this finding has not been
identified, but adherence to inhaled medication is a recog-
nised issue17 and patients may collect their medication
from a variety of pharmacies.Conflict of interest
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